Tris Pharma $7.5 Million Texas Settlement Over Dyanavel XR, What Parents and Patients Need to Know
Tris Pharma, Inc. and its CEO, Ketan Mehta, agreed to pay $7.5 million to the State of Texas to resolve a Medicaid-fraud enforcement lawsuit over the marketing of Dyanavel XR, an extended-release ADHD medication. Texas Attorney General Ken Paxton announced the settlement on October 1, 2026.
Is there a claim form? No. This is a state enforcement settlement, not a consumer class action. The money goes to Texas, so there is no claim form, no registration, no deadline, and no payment to individual patients or parents.
Do not stop or change a prescribed medication because of this news. Talk to the prescribing doctor about any medication decisions.
Quick Facts
| Detail | Information |
| Consumer claim form | None |
| Settlement website | None; no consumer settlement administrator |
| Who can claim | No one; money is paid to the State of Texas |
| Settlement amount | $7,500,000 |
| Paid by | Tris Pharma, Inc. and Ketan Mehta |
| Paid to | State of Texas (with a pro rata share to the federal government as required by law) |
| Drug | Dyanavel XR (amphetamine extended-release, ADHD) |
| Case | State of Texas, ex rel. Tarik Ahmed v. Tris Pharma, Inc. and Ketan Mehta |
| Cause number | 23-1030 |
| Court | 71st Judicial District Court, Harrison County, Texas |
| Type of case | Texas Medicaid fraud enforcement action (not a class action) |
| Settlement effective date | August 31, 2026 |
| Admission of wrongdoing | None; defendants deny the allegations |
| Payment schedule | Four payments of $1,875,000 through August 31, 2029 |
What Did Texas Allege?
The Texas Attorney General’s office says its investigation led to a 2023 lawsuit against Tris Pharma and Mehta. Texas alleged that Tris Pharma overstated the effectiveness of Dyanavel XR and directed sales representatives to make misleading statements to doctors, including providers in the Texas Medicaid program. The state said sales representatives promoted the idea that Dyanavel XR worked significantly faster than competing ADHD medications and made other benefit claims Texas said were unsupported. The state said these claims were made across thousands of sales calls.
The case was brought under the Texas Medicaid fraud statute, now called the Texas Health Care Program Fraud Prevention Act, which lets Texas pursue money paid through state health care programs when it alleges fraud.
These are allegations. The executed settlement says it is a compromise of disputed issues and is not an admission of facts, wrongdoing, or liability by Tris Pharma or Mehta.
Where Does the $7.5 Million Go?
Tris Pharma and Mehta agreed to pay $7,500,000 to the State of Texas as non-punitive compensation. The amount includes attorneys’ fees and expenses for the state and the whistleblower (called the relator), Tarik Ahmed. The agreement also provides for a pro rata share to go to the federal government as required by state and federal law.
The settlement does not create a consumer compensation fund. The headline figure should not be read as money available to Dyanavel XR patients.
Why There Is No Claim Form
You do not need to:
- Register for the settlement
- Submit a claim form
- Send prescription receipts to an administrator
- Pay anyone to “secure your share”
- Meet any settlement deadline
Be cautious about any website that asks for money or personal information to file a “Tris Pharma Dyanavel XR settlement claim.” This Texas agreement does not set up such a process. And because it is not a class action, there is no opt-out or objection process for consumers.
Payment Schedule
The agreement became effective August 31, 2026, the date of the last required signature. Tris Pharma and Mehta will pay in four installments:
| Payment | Amount | Due |
| First | $1,875,000 | September 15, 2026 |
| Second | $1,875,000 plus interest | August 31, 2027 |
| Third | $1,875,000 plus interest | August 31, 2028 |
| Fourth | $1,875,000 plus interest | August 31, 2029 |
Interest of 3.875% a year applies to the second, third, and fourth payments. The sources reviewed do not confirm whether Texas has received the first installment.
Within three business days after Texas receives the first payment, the state and the relator are to dismiss the case with prejudice. The Harrison County court keeps jurisdiction over any dispute about enforcing the settlement.
Does This Mean Dyanavel XR Is Unsafe?
No. The settlement is about alleged marketing and Medicaid-related conduct. It does not find that Dyanavel XR is unsafe for patients. FDA records identify Dyanavel XR as an amphetamine extended-release product for ADHD, and FDA pediatric information says safety and effectiveness were established in children ages 6 through 17.
Separately, in 2025 the FDA updated labeling for extended-release ADHD stimulants as a class, adding warnings about weight loss and other reactions in children younger than 6. That is a different matter from the Texas allegations.
If your child takes Dyanavel XR, do not stop it because of this settlement. If you have concerns about effectiveness or side effects, speak with the prescriber. You can report side effects to the FDA’s MedWatch program.
Does the Settlement Affect Individual Injury Claims?
The settlement does not decide whether anyone who used Dyanavel XR was injured or has a legal claim. It releases certain claims held by the state and the relator, but it also reserves some categories of claims, including claims the state may bring on behalf of individual consumers or state program payors under laws the release does not cover, and certain subrogation rights involving personal injury or property damage.
That means the settlement should not be read as ending every possible individual claim. It also does not guarantee anyone compensation. If you believe your child had a specific injury connected to the drug, keep medical records, prescription information, and communications with providers, and have the facts reviewed under the law and deadlines that apply to you.
Not the Same as the Quillivant XR Case
Do not confuse this with a separate Texas case. In November 2025, the Texas Attorney General announced a $41.5 million settlement with Pfizer and Tris Pharma over Quillivant XR, involving allegations about manufacturing practices and Texas Medicaid. That case had different allegations. The Dyanavel XR case is about alleged marketing claims on efficacy and speed of action.
Key Dates
| Date | Event |
| 2023 | Texas files suit; first amended petition filed November 8, 2023 |
| November 2025 | Separate $41.5M Quillivant XR settlement announced |
| August 25, 2026 | Defendant and relator-side signatures dated |
| August 31, 2026 | Texas signs; settlement effective |
| September 15, 2026 | First $1,875,000 payment due |
| October 1, 2026 | Texas Attorney General announces settlement |
| August 31, 2027 / 2028 / 2029 | Remaining payments due |
What Should Texas Families Do?
- Know that there is no claim to file and no deadline to meet.
- Keep giving the medication as prescribed unless the prescriber advises otherwise.
- Talk to your child’s doctor about any concerns.
- Avoid any site or caller asking for a fee to file a claim.
- If you believe there was a specific injury, keep medical records and have the facts reviewed on their own merits.
Frequently Asked Questions
Is there a Tris Pharma Dyanavel XR settlement claim form?
No. The $7.5 million Texas settlement has no consumer claim form or administrator.
Can Dyanavel XR patients receive part of the $7.5 million?
No direct payments are provided to patients. The money is payable to the State of Texas, with a pro rata share to the federal government.
Does the settlement mean Dyanavel XR is unsafe?
No. It resolves allegations about marketing and Texas Medicaid claims, not drug safety.
What did Texas allege?
That Tris Pharma overstated the drug’s effectiveness and told sales representatives to make misleading claims to doctors, including Texas Medicaid providers, such as claims about how fast it works.
Did Tris Pharma admit wrongdoing?
No. The agreement says it is not an admission of facts, wrongdoing, or liability, and the defendants deny the allegations.
What court handled the case?
The 71st Judicial District Court of Harrison County, Texas, Cause No. 23-1030.
Is it a class action?
No. It is a Texas enforcement action brought by the state with a whistleblower, Tarik Ahmed.
Do I need to opt out?
No. There is no consumer opt-out because it is not a consumer class settlement.
Can someone who believes Dyanavel XR harmed them still bring a claim?
The settlement does not decide that, and it reserves some categories of claims. Anyone considering a claim should have the facts and deadlines reviewed under the law that applies to them.
When will Tris Pharma finish paying?
Four installments of $1,875,000, the last due August 31, 2029, with interest on the later payments.
Related AllAboutLawyer Coverage
Looking for pharmaceutical settlements where consumers can claim money? See Generic Drug $96M Settlement, Deadline March 8, 2027. It is a separate case and is not connected to the Tris Pharma settlement.
Disclaimer: This article is for general informational purposes only and is not legal or medical advice. The settlement resolves disputed allegations and is not an admission of wrongdoing by Tris Pharma or Ketan Mehta. Consult a qualified healthcare professional about any medication.
About the Author: Israr Ahmad, Legal Content Researcher
Sources
- Texas Attorney General, “Attorney General Paxton Secures $7.5 Million Settlement from Tris Pharma for Misrepresenting the Efficacy of ADHD Drug for Kids,” October 1, 2026. https://oag.state.tx.us/news/releases/attorney-general-paxton-secures-75-million-settlement-tris-pharma-misrepresenting-efficacy-adhd-drug
- Executed Settlement Agreement and Release, State of Texas, Tarik Ahmed, Tris Pharma, Inc. and Ketan Mehta. https://oag.state.tx.us/sites/default/files/images/press/Executed%20Settlement.pdf
- Texas Attorney General, “Attorney General Ken Paxton Sues Pfizer and Tris Pharma for Defrauding Texas Medicaid and Providing Adulterated Pharmaceutical Drugs to Children.” https://www.texasattorneygeneral.gov/news/releases/attorney-general-ken-paxton-sues-pfizer-and-tris-pharma-defrauding-texas-medicaid-and-providing
- Texas Attorney General, “Attorney General Paxton Secures $41.5 Million from Pfizer and Tris Pharma for Providing Adulterated Drugs to Children.” https://www.texasattorneygeneral.gov/news/releases/attorney-general-paxton-secures-415-million-pfizer-and-tris-pharma-providing-adulterated-drugs
- U.S. Food and Drug Administration, Dyanavel XR labeling database entry. https://www.accessdata.fda.gov/scripts/sda/sdDetailNavigation.cfm?id=24E7D570748241C4E053554DA8C044F5&sd=labelingdatabase
- U.S. Food and Drug Administration, “Extended-Release Stimulants for ADHD: FDA Drug Safety Communication,” 2025. https://www.fda.gov/safety/medical-product-safety-information/extended-release-stimulants-adhd-fda-drug-safety-communication-fda-requires-expanded-labeling-about
About the Author
Israr Ahmad is a legal content researcher with 4+ years of experience covering class action settlements and consumer rights cases. He has researched and published coverage of 2,500+ settlements using verified court records, settlement administrator filings, and government sources. Learn more about Israr.